{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:46:04Z","timestamp":1792201564339,"version":"4.4.0"},"reference-count":31,"publisher":"FapUNIFESP (SciELO)","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiol Bras"],"abstract":"<jats:p>Abstract  Objective: To compare 68Ga-DOTA-DPhe1,Tyr3-octreotate (68Ga-DOTATATE) positron-emission tomography\/computed tomography (PET\/CT) findings with those of conventional 111In-octreotide scintigraphy in patients with neuroendocrine tumors (NETs).  Materials and Methods: This was a single-center prospective study including 41 patients (25 males; mean age, 55.4 years) with biopsy-proven NETs who underwent whole-body 111In-octreotide scintigraphy and whole-body 68Ga-DOTATATE PET\/CT. The patients had been referred for tumor staging (34.1%), tumor restaging (61.0%), or response evaluation (4.9%). Images were compared in a patient-by-patient analysis to identify additional lesions, and we attempted to determine the impact that discordant findings had on treatment planning.  Results: Compared with 111In-octreotide scintigraphy, 68Ga-DOTATATE PET\/CT revealed more lesions, the additional lesions typically being in the liver or bowel. Changes in management owing to the additional information provided by 68Ga-DOTATATE PET\/CT occurred in five patients (12.2%), including intermodal changes in three (7.3%) and intramodal changes in two (4.9%). In addition, 68Ga-DOTATATE PET\/CT yielded incidental findings unrelated to the primary NET in three patients (7.3%): H\u00fcrthle cell carcinoma of the thyroid, bowel non-Hodgkin lymphoma, and a suspicious breast lesion.  Conclusion: We conclude that 68Ga-DOTATATE PET\/CT is superior to conventional 111In-octreotide scintigraphy for the management of NETs because of its ability to determine the extent of the disease more accurately, which, in some cases, translates to changes in the treatment plan.<\/jats:p>","DOI":"10.1590\/0100-3984.2021.0038","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T12:04:05Z","timestamp":1644408245000},"page":"13-18","source":"Crossref","is-referenced-by-count":13,"title":["68Ga-DOTATATE PET\/CT versus 111In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study"],"prefix":"10.1590","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5592-7271","authenticated-orcid":false,"given":"Marcelo","family":"Cavicchioli","sequence":"first","affiliation":[{"name":"A.C. Camargo Cancer Center,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-9885","authenticated-orcid":false,"given":"Almir Galv\u00e3o Vieira","family":"Bitencourt","sequence":"additional","affiliation":[{"name":"A.C. Camargo Cancer Center,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-6964","authenticated-orcid":false,"given":"Eduardo N\u00f3brega Pereira","family":"Lima","sequence":"additional","affiliation":[{"name":"A.C. Camargo Cancer Center,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2022,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/erc.0.0110001","article-title":"Neuroendocrine tumours","volume":"11","author":"Barakat MT","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin IM","year":"2008","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.gtc.2016.04.007","article-title":"Neuroendocrine tumors","volume":"45","author":"Basuroy R","year":"2016","journal-title":"Gastroenterol Clin North Am"},{"issue":"Spec No A","key":"ref4","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1102\/1470-7330.2006.9038","article-title":"Nuclear medicine imaging and therapy of neuroendocrine tumours","volume":"6","author":"Gotthardt M","year":"2006","journal-title":"Cancer Imaging"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/eje.0.1510015","article-title":"Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours","volume":"151","author":"Kaltsas G","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.critrevonc.2009.02.009","article-title":"Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results","volume":"71","author":"Koopmans KP","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000225951","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs","volume":"90","author":"Kwekkeboom DJ","year":"2009","journal-title":"Neuroendocrinology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage JK","year":"2012","journal-title":"Gut"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00259-005-0006-1","article-title":"Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy","volume":"33","author":"Koukouraki S","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours","volume":"34","author":"Buchmann I","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel M","year":"2007","journal-title":"J Nucl Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11307-010-0374-1","article-title":"68Ga-DOTA-NOC PET\/ CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan\u00ae)","volume":"13","author":"Krausz Y","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2214\/AJR.11.7298","article-title":"Gallium-68-DOTA-NOC PET\/ CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study","volume":"197","author":"Naswa N","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.ejrad.2010.07.022","article-title":"PET-CT with 68Gallium-DOTA-peptides in NET: an overview","volume":"80","author":"Ambrosini V","year":"2011","journal-title":"Eur J Radiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","article-title":"Somatostatin receptor PET\/CT in neuroendocrine tumours: update on systematic review and meta-analysis","volume":"40","author":"Geijer H","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref16","first-page":"426","article-title":"The value of (68)Ga-DOTATATE PET\/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature","volume":"4","author":"Mojtahedi A","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2967\/jnumed.114.148247","article-title":"Impact of 68Ga-DOT-ATATE PET\/CT on the management of neuroendocrine tumors: the referring physician\u2019s perspective","volume":"56","author":"Herrmann K","year":"2015","journal-title":"J Nucl Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The impact of 68Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a National Referral Center in the United Kingdom","volume":"57","author":"Skoura E","year":"2016","journal-title":"J Nucl Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","author":"Sadowski SM","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.115.165803","article-title":"68Ga-DOTATATE compared with 111In-DTPA-Octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"57","author":"Deppen SA","year":"2016","journal-title":"J Nucl Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2967\/jnumed.116.185587","article-title":"The impact of somatostatin receptor-directed PET-CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis","volume":"58","author":"Barrio M","year":"2017","journal-title":"J Nucl Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/RLU.0000000000002309","article-title":"ACR practice parameter for the performance of gallium-68 DOTATATE PET\/CT for neuroendocrine tumors","volume":"43","author":"Subramaniam RM","year":"2018","journal-title":"Clin Nucl Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.109.071712","article-title":"68Ga-DOTANOC PET\/ CT clinical impact in patients with neuroendocrine tumors","volume":"51","author":"Ambrosini V","year":"2010","journal-title":"J Nucl Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1536-1632(03)00038-6","article-title":"Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors","volume":"5","author":"Kowalski J","year":"2003","journal-title":"Mol Imaging Biol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy","volume":"51","author":"Srirajaskanthan R","year":"2010","journal-title":"J Nucl Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1754-9485.2011.02327.x","article-title":"High management impact of Ga-68-DOTATATE (GaTate) PET\/CT for imaging neuroendocrine and other somatostatin expressing tumours","volume":"56","author":"Hofman MS","year":"2012","journal-title":"J Med Imaging Radiat Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.surg.2018.03.030","article-title":"68Gallium-DOTATATE positron emission tomography-computed tomography (PET CT) changes management in a majority of patients with neuroendocrine tumors","volume":"165","author":"Tierney JF","year":"2019","journal-title":"Surgery"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jso.25812","article-title":"Impact of initial imaging with gallium-68 dotatate PET\/CT on diagnosis and management of patients with neuroendocrine tumors","volume":"121","author":"Crown A","year":"2020","journal-title":"J Surg Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4274\/Mirt.80299","article-title":"Improved benefit of SPECT\/CT compared to SPECT alone for the accurate localization of endocrine and neuroendocrine tumors","volume":"21","author":"Bural GG","year":"2012","journal-title":"Mol Imaging Radionucl Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2214\/AJR.18.19881","article-title":"Neuroendocrine tumor diagnosis and management: 68Ga-DOTATATE PET\/CT","volume":"211","author":"Sanli Y","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2217\/fon-2017-0393","article-title":"The utility of 68Ga-DOTATATE positronemission tomography\/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors","volume":"14","author":"Tirosh A","year":"2018","journal-title":"Future Oncol"}],"container-title":["Radiologia Brasileira"],"original-title":[],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T12:04:37Z","timestamp":1644408277000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-39842022000100013&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["S0100-39842022000100013"],"URL":"https:\/\/doi.org\/10.1590\/0100-3984.2021.0038","relation":{},"ISSN":["1678-7099"],"issn-type":[{"value":"1678-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}